A comprehensive narrative review published in Cardiology Discovery outlines major recent progress and remaining gaps in care for hypertrophic cardiomyopathy (HCM), a common predominantly inherited heart muscle disorder that can trigger sudden cardiac death in young patients. While older therapies focused mainly on easing symptoms, newer targeted medications, refined interventional techniques, and investigational genetic approaches now offer expanded treatment pathways for both obstructive and non‑obstructive HCM patient subgroups.
HCM is driven largely by sarcomere‑gene mutations that produce excessive myocardial contraction, thickened heart walls, scarring, and, in many patients, left‑ventricular outflow‑tract obstruction. For decades, beta‑blockers and calcium‑channel blockers formed main‑stay therapy; these agents improve symptoms but cannot reverse core pathological changes. Many patients continue to have disabling symptoms despite standard‑of‑care medical management, creating unmet clinical needs, especially for people living with non‑obstructive HCM with limited approved drug options.
This analysis represents a narrative literature review rather than original patient trial data. Investigators from Peking Union Medical College Hospital performed a structured search across PubMed, Embase, and Web of Science covering publications from January 2010 through June 2026. The team synthesized randomized clinical‑trial outputs, systematic reviews, and clinical guidelines. Pre‑clinical laboratory and animal‑model findings were included only when considered relevant for clinical translation, and are clearly marked as pre‑clinical findings, not ready for broad human clinical use. The work covers pharmacotherapy, invasive septal‑reduction interventions, gene‑based strategies, risk stratification, and updated exercise guidance for adult HCM patients.
Cardiac myosin inhibitors mark a key clinical advance. Mavacamten, the first‑in‑class agent, has gained global regulatory approval for symptomatic obstructive HCM. In the VALOR‑HCM trial, only 18% of treated patients still met criteria for septal‑reduction therapy after 16 weeks, compared with 77% receiving placebo. The second agent aficamten also demonstrated significant improvements in exercise capacity and reverse cardiac remodeling in phase‑3 testing. Meanwhile, multiple metabolic modulators, anti‑fibrotic compounds, sodium‑glucose cotransporter‑2 inhibitors, and minimally‑invasive interventional techniques are under active clinical evaluation. Promising gene‑replacement, gene‑editing, and gene‑silencing strategies remain largely pre‑clinical, with the TN‑201 gene‑replacement therapy now entering early‑phase human trials. Updated international guidelines also support safe moderate‑intensity recreational exercise for most low‑risk HCM patients.
Important limitations must be emphasized. This is a descriptive synthesis of existing published evidence. While cardiac myosin inhibitors have robust randomized trial support, most emerging metabolic, anti‑fibrotic, and gene‑directed therapies are in pre‑clinical or early‑phase human investigation and lack long‑term safety and hard clinical‑outcome data. Direct head‑to‑head treatment comparisons are scarce. Widespread clinical roll‑out for gene therapies will require solving delivery hurdles, potential off‑target effects, and cost‑effectiveness questions. Further large prospective trials are needed to define optimal patient selection for new interventions.
Article citation:
Ren X, Tian Z, Zhang S. Recent Advances and Future Perspectives in the Treatment of Hypertrophic Cardiomyopathy. Cardiology Discovery. 2026. DOI: 10.1097/CD9.0000000000000207
Cardiology Discovery
Literature review
Not applicable
Recent Advances and Future Perspectives in the Treatment of Hypertrophic Cardiomyopathy
10-Aug-2026